{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:18:57Z","timestamp":1792451937926,"version":"4.5.0"},"reference-count":62,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hepatitis C virus (HCV) still represents one of the most important worldwide health care problems. Since 2011, direct-acting antiviral (DAA) drugs have increased the number of people who have achieved a sustained virological response (SVR). Even if the program to eradicate HCV by 2030 is still ongoing, the SARS-CoV-2 pandemic has created a delay due to the reallocation of public health resources. HCV is characterized by high genetic variability and is responsible for hepatic and extra-hepatic diseases. Depending on the HCV genotype\/subtype and comorbidities of patients, tailored treatment is necessary. Recently, it has been shown that liver damage impacts gut microbiota, altering the microbial community (dysbiosis) during persistent viral replication. An increasing number of studies are trying to clarify the role of the gut\u2013liver axis during HCV chronic infection. DAA therapy, by restoring the gut microbiota equilibrium, seems to improve liver disease progression in both na\u00efve and treated HCV-positive patients. In this review, we aim to discuss a snapshot of selected peer-reviewed papers concerning the interplay between HCV and the gut\u2013liver axis.<\/jats:p>","DOI":"10.3390\/jcm11195936","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T23:39:31Z","timestamp":1665272371000},"page":"5936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Role of the Microbiota Gut\u2013Liver Axis during HCV Chronic Infection: A Schematic Overview"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0880-8955","authenticated-orcid":false,"given":"Nadia","family":"Marascio","sequence":"first","affiliation":[{"name":"Clinical Microbiology Unit, Department of Health Science, \u201cMagna Graecia\u201d University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-5958","authenticated-orcid":false,"given":"Carmen","family":"De Caro","sequence":"additional","affiliation":[{"name":"System and Applied Pharmacology, Department of Health Science, \u201cMagna Graecia\u201d University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Quirino","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Department of Health Science, \u201cMagna Graecia\u201d University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0703","authenticated-orcid":false,"given":"Maria","family":"Mazzitelli","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, University Hospital of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-8123","authenticated-orcid":false,"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[{"name":"System and Applied Pharmacology, Department of Health Science, \u201cMagna Graecia\u201d University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7631-5453","authenticated-orcid":false,"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, \u201cMagna Graecia\u201d University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Matera","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Department of Health Science, \u201cMagna Graecia\u201d University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2022, August 05). Available online: https:\/\/www.who.int."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Van Dijk, M., Brakenhoff, S.M., Isfordink, C.J., Cheng, W.H., Blokzijl, H., Boland, G., Dofferhoff, A.S.M., van Hoek, B., van Nieuwkoop, C., and Sonneveld, M.J. (2021). The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194562"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3748\/wjg.v28.i12.1226","article-title":"Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice","volume":"28","author":"Marascio","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13027-016-0076-7","article-title":"Systemic manifestations of hepatitis C Infection","volume":"11","author":"Tang","year":"2016","journal-title":"Infect Agent Cancer."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3350\/cmh.2018.0061","article-title":"Discussion on critical points for a tailored therapy to cure hepatitis C virus infection","volume":"25","author":"Marascio","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.31700","article-title":"Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients without Liver Cirrhosis","volume":"74","author":"Woelfl","year":"2021","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12016-019-08731-2","article-title":"Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis","volume":"58","author":"Chen","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/apt.15795","article-title":"Editorial: Gut microbiota profile in patients with autoimmune hepatitis-aclue for adjunctive probiotic therapy?","volume":"52","author":"Granito","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/cmi.12308","article-title":"Defining dysbiosis and its influence on host immunity and disease","volume":"16","author":"Petersen","year":"2014","journal-title":"Cell Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1021\/acsinfecdis.0c00432","article-title":"Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection","volume":"7","author":"Sultan","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/apt.15004","article-title":"Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis","volume":"48","author":"Ponziani","year":"2018","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1002\/cam4.3045","article-title":"Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma","volume":"9","author":"Zheng","year":"2020","journal-title":"Cancer Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"El-Mowafy, M., Elgaml, A., El-Mesery, M., Sultan, S., Ahmed, T.A.E., Gomaa, A.I., Aly, M., and Mottawea, W. (2021). Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology, 10.","DOI":"10.3390\/biology10010055"},{"key":"ref_16","first-page":"263","article-title":"Liver injury and disease pathogenesis in chronic hepatitis C","volume":"369","author":"Yamane","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1665-2681(19)31720-X","article-title":"Routes of transmission of hepatitis C virus","volume":"9","author":"Soza","year":"2010","journal-title":"Ann Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e25348","DOI":"10.1002\/jia2.25348","article-title":"Sexually transmitted hepatitis C virus infections: Current trends, and recent advances in understanding the spread in men who have sex with men","volume":"22","author":"Nijmeijer","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"a036921","DOI":"10.1101\/cshperspect.a036921","article-title":"Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy","volume":"10","author":"Negro","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2174\/138920111798377030","article-title":"Mechanisms involved in the development of chronic hepatitis C as potential targets of antiviral therapy","volume":"12","author":"Jackowiak","year":"2011","journal-title":"Curr Pharm. Biotechnol."},{"key":"ref_22","first-page":"219","article-title":"Innate immune responses to hepatitis C virus","volume":"369","author":"Schoggins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.3748\/wjg.v19.i44.7896","article-title":"An insight into the diagnosis and pathogenesis of hepatitis C virus infection","volume":"19","author":"Irshad","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/bmj.332.7538.374","article-title":"Clinical course of infection with hepatitis C is still poorly understood","volume":"332","author":"Vento","year":"2006","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12846","DOI":"10.1038\/s41598-019-49258-y","article-title":"Hepatitis C virus (HCV) genotype 1b displays higher genetic variability of hypervariable region 1 (HVR1) than genotype 3","volume":"9","author":"Janiak","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12664-018-0920-3","article-title":"Hepatitis C virus infection and chronic renal disease: A review","volume":"37","author":"Goel","year":"2018","journal-title":"Indian J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Khatun, M., and Ray, R.B. (2019). Mechanisms underlying hepatitis C virus-associated hepatic fibrosis. Cells, 8.","DOI":"10.3390\/cells8101249"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e41933","DOI":"10.5812\/hepatmon.41933","article-title":"The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?","volume":"16","author":"Strazzulla","year":"2016","journal-title":"Hepat. Mon."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature11552","article-title":"Functional interactions between the gut microbiota and host metabolism","volume":"489","author":"Tremaroli","year":"2012","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1073\/pnas.1619598114","article-title":"Effect of water flow and chemical environment on microbiota growth and composition in the human colon","volume":"114","author":"Cremer","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/db11-0846","article-title":"Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3","volume":"61","author":"Li","year":"2012","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"G413","DOI":"10.1152\/ajpgi.00361.2016","article-title":"Gut-liver axis at the frontier of host-microbial interactions","volume":"312","author":"Brandl","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile Acid Metabolism in Liver Pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000450982","article-title":"Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling","volume":"35","author":"Marschall","year":"2017","journal-title":"Dig. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1073\/pnas.1006734107","article-title":"Systemic gut microbial modulation of bile acid metabolism in host tissue compartments","volume":"108","author":"Swann","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17474124.2019.1569513","article-title":"Gut microbiota: Novel therapeutic target for nonalcoholic fatty liver disease","volume":"13","author":"Suk","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2012-302578","article-title":"Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases","volume":"62","author":"Duboc","year":"2013","journal-title":"Gut"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","article-title":"Lipid alterations in chronic liver disease and liver cancer","volume":"4","author":"Paul","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cid\/ciy205","article-title":"Gut Dysbiosis associated with hepatitis C virus infection","volume":"67","author":"Inoue","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17474124.2017.1343663","article-title":"Gut microbiota changes and chronic hepatitis C virus infection","volume":"11","author":"Preveden","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gupta, H., Youn, G.S., Shin, M.J., and Suk, K.T. (2019). Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms, 7.","DOI":"10.20944\/preprints201903.0267.v1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13099-016-0124-2","article-title":"Gut microbiome alterations in patients with stage 4 hepatitis C","volume":"8","author":"Aly","year":"2016","journal-title":"Gut Pathog."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2019.06.005","article-title":"Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients","volume":"67","author":"Morano","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/liv.13485","article-title":"Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls","volume":"38","author":"Heidrich","year":"2018","journal-title":"Liver Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/IAI.00188-08","article-title":"The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis","volume":"76","author":"Cosseau","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL recommendations on treatment of hepatitis C 2016. J. Hepatol., 66, 153\u2013194.","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tim.2010.11.005","article-title":"Assembly of infectious hepatitis C virus particles","volume":"19","author":"Bartenschlager","year":"2011","journal-title":"Trends Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/1060028017704857","article-title":"Hepatitis C virus resistance testing in genotype 1, the changing role in clinical utility","volume":"51","author":"Molino","year":"2017","journal-title":"Ann Pharmacother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/apt.13732","article-title":"HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients","volume":"44","author":"Bajaj","year":"2016","journal-title":"Aliment. Pharmacol Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.femsre.2004.09.003","article-title":"The interaction between bacteria and bile","volume":"29","author":"Begley","year":"2005","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immune histochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"Aghemo","year":"2012","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Yilmaz, B., Ruckstuhl, L., M\u00fcllhaupt, B., Magenta, L., Kuster, M.H., Clerc, O., Torgler, R., and Semmo, N. (2021). Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir\/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090931"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.livres.2019.02.001","article-title":"The role of gut microbiota in liver disease development and treatment","volume":"3","author":"Wang","year":"2019","journal-title":"Liver Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Bajaj, J.S., Heuman, D.M., Sanyal, A.J., Hylemon, P.B., Sterling, R.K., Stravitz, R.T., Fuchs, M., Ridlon, J.M., Daita, K., and Monteith, P. (2013). Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060042"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coviro.2019.05.007","article-title":"Virome and bacteriome: Two sides of the same coin","volume":"37","author":"Stern","year":"2019","journal-title":"Curr. Opin. Virol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:10Z","timestamp":1760143690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":62,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11195936"],"URL":"https:\/\/doi.org\/10.3390\/jcm11195936","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]}}}